PetMeds Board Of Directors Has Adopted A Limited Duration Shareholder Rights Plan To Protect The Best Interests Of All PetMeds Shareholders, Effective Immediately And Will Expire On December 2, 2025
PetMeds Board Of Directors Has Adopted A Limited Duration Shareholder Rights Plan To Protect The Best Interests Of All PetMeds Shareholders, Effective Immediately And Will Expire On December 2, 2025
PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) ("PetMeds" or the "Company"), today announced that its Board of Directors (the "Board") has adopted a limited duration shareholder rights plan to protect the best interests of all PetMeds shareholders (the "Rights Plan").
PetMed Express, Inc.以PetMeds的名義運營,並且是PetCareRx(納斯達克:PETS)的母公司("PetMeds"或"公司"),今天宣佈其董事會("董事會")已通過一項有限期限股東權利計劃,以保護所有PetMeds股東("權利計劃")的最佳利益。
The Board adopted the Rights Plan to protect the investment of shareholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential, and during which there have been recent significant accumulations of Company common stock by certain shareholders.
董事會通過權利計劃是爲了保護股東在公司股票未能反映業務的內在價值或長期增長潛力的期間所做的投資,並且在此期間,某些股東對公司普通股的積累顯著增加。
The Rights Plan is intended to enable PetMeds shareholders to realize the long-term value of their investment in the Company by reducing the likelihood that any entity, person, or group is able to gain a control or control-like position in the Company through open market accumulation without paying all shareholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take actions that are in the best interests of all shareholders. The rights plan does not prevent any action that the Board determines to be in the best interest of the Company and its shareholders.
權利計劃旨在使PetMeds股東能夠實現其在公司投資的長期價值,從而降低任何實體、個人或團體通過公開市場積累獲得控股或類似控制權的可能性,而不向所有股東支付適當的控制溢價或給予董事會足夠的機會做出明智的判斷並採取符合所有股東最佳利益的行動。該權利計劃並不阻止董事會決定的任何被視爲公司及其股東最佳利益的行動。
The Rights Plan is not intended to interfere with any sale, merger, tender, exchange offer or other business combination approved by the Board. Nor does the Rights Plan prevent the Board from considering any offer that recognizes the full value of PetMeds and is in the best interests of PetMeds' shareholders.
權利計劃並不打算干擾董事會批准的任何出售、合併、要約收購、交換要約或其他業務組合。同時,權利計劃也不阻止董事會考慮任何承認PetMeds全部價值且符合PetMeds股東最佳利益的要約。
Pursuant to the Rights Plan, PetMeds will issue, by means of a dividend, one right for each outstanding share of PetMeds common stock to shareholders of record on the close of business on December 16, 2024. Initially, these rights will not be exercisable and will trade with, and be represented by, the shares of PetMeds common stock.
根據權利計劃,PetMeds將通過分紅的方式爲在2024年12月16日營業結束時的記錄股東每持有一股PetMeds普通股發行一份權利。最初,這些權利將不可行使,並將隨PetMeds普通股交易,並由其代表。
The Rights Plan is effective immediately and will expire on December 2, 2025, or earlier, as provided in the Rights Plan.
權利計劃立即生效,並將於2025年12月2日或更早如權利計劃所述到期。
譯文內容由第三人軟體翻譯。